Red cell alloimmunisation challenges the provision of compatible donor blood and, most importantly, might induce severe haemolytic transfusion reactions (Serious Hazards Of Transfusion \[SHOT\], [2014](#bjh14307-bib-0032){ref-type="ref"}; Transfusion and Transplantation Reactions In Patients \[TRIP\], [2014](#bjh14307-bib-0035){ref-type="ref"}). Consequently, some selected patients receive extensively matched blood (Dutch Institute for Healthcare Improvement \[CBO\], [2011](#bjh14307-bib-0006){ref-type="ref"}; United Kingdom Blood Services, [2013](#bjh14307-bib-0036){ref-type="ref"}). Despite the effectiveness of these risk‐based matching practices (Vichinsky *et al*, [2001](#bjh14307-bib-0037){ref-type="ref"}; Lasalle‐Williams *et al*, [2011](#bjh14307-bib-0022){ref-type="ref"}; Schonewille *et al*, [2015](#bjh14307-bib-0031){ref-type="ref"}), non‐selected patients do experience alloimmunisation‐mediated complications (Harvey *et al*, [2014](#bjh14307-bib-0013){ref-type="ref"}; TRIP, [2014](#bjh14307-bib-0035){ref-type="ref"}; SHOT, [2015](#bjh14307-bib-0033){ref-type="ref"}) warranting consideration of additional risk factors.

In addition to the chance of encountering a high immunogenic non‐self antigen (Evers *et al*, [2016](#bjh14307-bib-0009){ref-type="ref"}), clinical conditions affecting the recipient\'s immune response probably modulate alloimmunisation. Identification of such factors might enable allocating extensively matched blood principally to high‐risk patients.

Experimentally induced inflammation has consistently been demonstrated as a major determinant of red cell alloimmunisation in mice (Hendrickson *et al*, [2006](#bjh14307-bib-0015){ref-type="ref"}, [2007](#bjh14307-bib-0016){ref-type="ref"}; Hendrickson, 2008; Smith *et al*, [2012](#bjh14307-bib-0034){ref-type="ref"}). In line with this, pro‐inflammatory conditions related to sickle cell disease as well as febrile reactions to donor platelets were shown to enhance alloimmunisation in humans (Yazer *et al*, [2009](#bjh14307-bib-0042){ref-type="ref"}; Fasano *et al*, [2015](#bjh14307-bib-0010){ref-type="ref"}). Apart from one case report (Hata *et al*, [2013](#bjh14307-bib-0014){ref-type="ref"}) to the best of our knowledge, the influence of infection‐associated inflammation on red cell alloimmunisation in humans has not been reported.

In this nested case--control study, we quantified relative alloimmunisation risks for patients receiving red cell units during an infectious episode, according to the type of infection, its intensity, and the patient\'s inflammatory response to it.

Patients and methods {#bjh14307-sec-0002}
====================

Study design and setting {#bjh14307-sec-0003}
------------------------

We performed a nested case--control study within a source population of previously non‐transfused and non‐alloimmunised patients in three university hospitals and three reference hospitals in the Netherlands. Using this design, we compared patients who developed red cell alloantibodies following transfusion with non‐alloimmunised controls on the basis of supposed causal attributes, including various types of infections. Details on the source population, including its eligibility criteria, and our case--control study design have been previously published (Zalpuri *et al*, [2012a](#bjh14307-bib-0043){ref-type="ref"}; Evers *et al*, [2016](#bjh14307-bib-0009){ref-type="ref"}).

To summarize, patients were eligible if they received their first red cell transfusion during the study period in one of the participating hospitals, provided this transfusion was preceded by a negative antibody screen and followed by an antibody screen, hereby permitting evaluation of alloantibody development. The study period per hospital depended on electronic availability of the necessary data between 1 January 2005 and 31 December 2013 (for details, see Data S1). All red cell units were prepared by buffy‐coat depletion of whole blood donations, subsequently filtered through a leucocyte depletion filter, and stored in saline, adenine, glucose, and mannitol (SAGM) for a maximum of 35 days (CBO, [2011](#bjh14307-bib-0006){ref-type="ref"}).

A patient was defined as a case upon developing a first, transfusion‐induced red cell alloantibody directed against one of the following antigens: c, C, e, E, K, C^w^, Fy^a^, Fy^b^, Jk^a^, Jk^b^, Lu^a^, Lu^b^, M, N, S or s. Anti‐D immunised patients were not taken into consideration because we were unable to discriminate whether anti‐D was caused by unmatched transfusions, or (mainly regarding fertile women) was due to recent anti‐D administration in the context of a D‐positive pregnancy or transfusion. Patients who formed antibodies, yet either lacked exposure to a (documented or assumed) antigen‐positive red cell unit or expressed the antigen themselves (i.e. auto‐immunised patients) were deemed ineligible. In addition, alloimmunised patients were excluded if their first‐time alloantibody positive screen occurred within 7 days of the first mismatched transfusion, as these were more likely to represent boosting of earlier primary immunisations. By consulting the nationwide alloimmunisation registry (<http://www.sanquin.nl/producten-diensten/diagnostiek/trix>), we additionally excluded patients previously diagnosed with alloimmunisation in other hospitals. Considering the above‐mentioned criteria, we specifically aimed to exclude previously alloimmunised patients, including pregnancy‐induced immunisations in women. Finally, haemoglobinopathy patients and infants below 6 months of age were not included.

Each eligible case was matched to two randomly selected non‐alloimmunised control patients based on the hospital and on the (lifetime) number of red cell transfusions received at the time of alloimmunisation. This 'incidence‐density sampling strategy' ensured that controls were exposed to at least the same amount of transfusions as their matched cases and thus formed a representative sample of the source population (Rothman, [2007](#bjh14307-bib-0030){ref-type="ref"}).

For all cases, we assumed that the last antigen‐mismatched transfusion (the '*Nth'* or implicated transfusion) preceding the first positive screen most likely elicited alloimmunisation. If this last mismatched transfusion could not be identified due to incomplete typing of donor units, we assumed the last non‐tested unit preceding the first positive screen by at least 7 days to have elicited alloimmunisation. An 'alloimmunisation risk period' was then constructed, stretching from 30 days before up to 7 days after this implicated *Nth* transfusion. A similar risk period around the *Nth* transfusion was determined for the matched controls. The implicated transfusion and its alloimmunisation risk period are illustrated in Fig [1](#bjh14307-fig-0001){ref-type="fig"}.

![The implicated transfusion and alloimmunisation risk period. The last antigen‐mismatched transfusion preceding the first serological detection of an antibody was defined as the 'implicated (or *Nth*) transfusion' since this transfusion was the most likely to influenc alloimmunisation. To exclude possible boosting events, this implicated transfusion was required to precede the first positive screen by at least 7 days (i.e. lag period). An alloimmunisation risk period was then constructed starting 30 days before and finishing 7 days after this implicated transfusion. Controls received at least the same number of red cell units as their matched case. A similar alloimmunisation risk period around the *Nth* matched transfusion was constructed.](BJH-175-956-g001){#bjh14307-fig-0001}

For all cases and controls, we recorded various clinical conditions during the alloimmunisation risk period.

The study protocol was approved by the Ethical Review Board at the Leiden University Medical Centre in Leiden and by the local board of each participating centre.

First‐formed red cell alloantibodies {#bjh14307-sec-0004}
------------------------------------

Patients in the Netherlands are routinely screened for red cell alloantibodies at a maximum of 72 h prior to red cell transfusion. According to the Dutch transfusion guideline (CBO, [2011](#bjh14307-bib-0006){ref-type="ref"}), commercially available 3‐cell screening panels are required to be homozygous positive for D, C, c, E, e, K, Fy^a^, Fy^b^, Jk^a^, Jk^b^, M, S and s. The presence of the K antigen in its heterozygous form is a minimum requirement. The presence of C^w^, Lu^a^, Wr^a^, and Kp^a^ is not mandatory on commercially available screening cells (CBO, [2011](#bjh14307-bib-0006){ref-type="ref"}). Antibody screening involves a three‐cell panel using an indirect antiglobulin test \[column agglutination technology from either BioRad (Cressier, Switzerland), or Ortho Clinical Diagnostics (Raritan, NJ, USA)\]. If positive, screening is followed by subsequent antibody identification by an 11‐cell panel using the same technique.

Data acquisition {#bjh14307-sec-0005}
----------------

We gathered routinely stored data on red cell transfusion dates, dates and results of antibody screens (including antibody specificity), patients' date of birth, sex and leucocyte counts from the hospitals' electronic laboratory information systems. In addition, we examined the medical charts of all cases and controls for the presence of various potential clinical risk variables during the alloimmunisation risk period, including dates of infection, the causative microorganisms, dates of fever (temperature ≥38·5°C), leucocyte counts, and C‐reactive protein (CRP) values.

Bacterial infections comprised tissue‐invasive infections (i.e. involving an anatomic site location) and bacteraemia (i.e. involving positive blood cultures).

Tissue‐invasive bacterial infections were considered present when confirmed by either a positive blood or tissue culture, or when a suspected clinical infectious phenotype was supported by an overtly disease‐specific radiographic anomaly e.g. a clear lobar consolidation on a chest x‐ray in a patient with fever and cough. We categorized these infections into 'mild' or 'severe' according to their expected degree of systemic inflammation. Mild tissue‐invasive bacterial infections included: routine (tip) cultures from central catheters, catheter‐induced phlebitis, lower urinary tract infections, bacterial enteritis, skin and superficial wound infections, and upper respiratory tract infections. 'Severe' tissue‐invasive bacterial infections included: abscesses, intra‐abdominal infections including spontaneously or secondarily infected abdominal fluid collections, arthritis, bursitis, myositis, fasciitis, infected haematoma, bacterial meningitis, deep wound or skin infections, endocarditis, mediastinitis, pericarditis, infected foreign material, lower respiratory tract infections, osteomyelitis, spondylodiscitis and upper urinary tract infections.

Bacteraemia were categorized according to their Gram‐positive or Gram‐negative causative microorganism.

For the qualification of a viral infection, a positive polymerase chain reaction (PCR) test demonstrating the replication of viral RNA or DNA was needed or, in case a PCR test was not performed, the clinical condition needed to be clearly virally induced, e.g. herpes labialis. Viraemia and disseminated viral zoster infections were defined as 'disseminated viral infections', in contrast to 'local viral infections', which were restricted to one anatomic site location.

Statistical analyses {#bjh14307-sec-0006}
--------------------

The associations of various infections with the development of red cell alloimmunisation were evaluated using logistic regression analyses. For crude relative risk (RR) calculations, we conditioned on the matched variables, i.e. hospital and cumulative number of red cell units received.

For multivariate analyses, we also conditioned on measured confounders, taking into account that a confounder meets the prerequisites of being associated with the exposure (i.e. infections) in the source population, is (a marker for) a causal risk factor of the outcome (i.e. alloimmunisation) and is not in the causal pathway between the exposure and the outcome (Hernan *et al*, [2002](#bjh14307-bib-0018){ref-type="ref"}; Middelburg *et al*, [2014](#bjh14307-bib-0027){ref-type="ref"}). Consequently, we used the following strategy. First, we identified a subset of covariates to be confounders of a given determinant based on their observed association with the determinant within the source population (i.e. the non‐alloimmunised controls). Such an association was defined as a ≥3% difference in covariate presence between controls exposed and controls not exposed to the determinant. Covariates in the causal pathway between the determinant and the outcome were not considered as confounders (Hernan *et al*, [2002](#bjh14307-bib-0018){ref-type="ref"}). Second, to be able to accurately control for confounders with low prevalences, we estimated a probability score for each determinant using logistic regression with the potential confounders as predictors (Brookhart *et al*, [2013](#bjh14307-bib-0004){ref-type="ref"}). Third, to minimize bias due to missing data on the confounders, we used multiple imputation. Details on the used imputation model can be found in the Data S1 and Table SI. Finally, we evaluated the association between various types of infections and red cell alloimmunisation by subsequently entering the corresponding probability scores into the logistic regression model with alloimmunisation as the outcome and conditioning on the matched variables.

We next assessed the association of level of CRP values and leucocytosis as possible markers of inflammation with red cell alloimmunisation. Leucocytosis was categorized as maximum measured leucocyte counts of 10--15, 15--20, 20--30 and \>30 × 10^9^/l, and referenced to normal counts (4--10 × 10^9^/l). Maximum measured CRP values were categorized as 30--100, 100--200, 200--300 and \>300 mg/l, and referenced to values ≤30 mg/l. Missing CRP and leucocyte values were multiply imputed using the same strategy as described above. While the likelihood that an increased inflammatory parameter has been recorded at least once increases with the number of measurements and thus with the duration of hospitalization, we repeated these analyses limited to parameters measured within the week following the implicated transfusion. As elevated CRP levels and leucocytosis reflect various clinical conditions preventing causal inferences, they are presented here only as unadjusted RRs.

As anti‐E, anti‐C^w^, anti‐Le^a^, anti‐Le^b^, anti‐Lu^a^, and anti‐M can also form 'naturally' (e.g. directly in response to microbial epitope exposure (Reid *et al*, [2004](#bjh14307-bib-0029){ref-type="ref"}), we evaluated a possible association between the presence of these antibodies and various types of infections using Pearson\'s chi‐square test. *P*‐values \<0·05 were considered to be statistically significant.

As we used an incidence‐density sampling procedure to select controls (Rothman, [2007](#bjh14307-bib-0030){ref-type="ref"}), we interpreted and present all odds ratios as RRs with 95% confidence intervals (95% CI).

Sensitivity analyses {#bjh14307-sec-0007}
--------------------

For some patients, the presence or absence of a certain type of infection could not be determined. These patients were left out of the corresponding analysis. Regarding severe bacterial infections, we performed a sensitivity analysis in which these patients were alternately assigned to exposure and non‐exposure of this infection.

For patients with a suspected lower respiratory infection without conclusive or available cultures, we considered this infection to be due to a bacterial microorganism. Although viral or (rarely) fungal pathogens may cause pneumonia, bacterial microorganisms are the most common cause in Dutch hospitalised patients, with *Streptococcus Pneumoniae* and *Haemophilus Influenzae* alone representing 30--75% of causative pathogens (Wiersinga *et al*, [2012](#bjh14307-bib-0041){ref-type="ref"}).

Finally, as contaminated blood cultures positive for coagulase‐negative staphylococci (CNS) might dilute an existing effect of Gram‐positive bacteraemia, we compared RRs for all Gram‐positive bacteraemia with those for non‐CNS Gram‐positive bacteraemia.

Results {#bjh14307-sec-0008}
=======

Among 54 347 newly‐transfused patients, 24 063 were considered eligible (Fig S1) of which 505 patients (2·1%) formed red‐cell alloantibodies. Thirty‐seven of these alloimmunised patients (7·3%) only received units of which the cognate antigen was unknown. For these, we assumed the last non‐tested unit preceding the first positive screen to have elicited alloimmunisation.

General and clinical characteristics of the 505 cases and their 1010 matched controls during the alloimmunisation risk period are presented in Table [1](#bjh14307-tbl-0001){ref-type="table"}.

###### 

Patient characteristics during the alloimmunisation risk period

  Characteristics                                                                                      Cases (*N* = 505)   Controls (*N* = 1010)   Missing data
  ---------------------------------------------------------------------------------------------------- ------------------- ----------------------- --------------
  Male                                                                                                 237 (46·9)          568 (56·2)              
  Age, years (median, IQR)                                                                             67·0 (55·0--75·9)   65·3 (51·6--75·1)       
  Transfused in a university hospital                                                                  232 (45·9)          464 (45·9)              
  Cumulative (lifetime) number of red cell units up to implicated transfusion, median (IQR)            4 (2--8)            4 (2--8)                
  Single transfused, *N* (%)                                                                           26 (5·1)            7 (0·7)                 
  Follow‐up (days) up till last screen, median (IQR)                                                   92 (20--193)        117 (10--609)           
  Cumulative number of red cell units during risk period, median (IQR)                                 3 (2--6)            4 (2--8)                
  Days transfused during risk period, median, (IQR)                                                    1 (1--3)            2 (1--3)                
  ICU admission                                                                                        177 (36·5)          369 (35·0)              
  Days at ICU, median (IQR)                                                                            7 (2--18)           7 (2--17)               4
  Surgery                                                                                              267 (52·9)          457 (45·2)              2
  Thoracic including CABG                                                                              61 (12·1)           144 (14·3)              
  Abdominal                                                                                            100 (19·8)          181 (17·9)              
  Back or spinal cord                                                                                  3 (0·6)             11 (1·1)                
  Diabetes mellitus type 1                                                                             6 (1·2)             7 (0·7)                 
  Diabetes mellitus type 2                                                                             91 (18·0)           176 (17·4)              1
  Atherosclerosis[a](#bjh14307-note-0004){ref-type="fn"}                                               198 (39·5)          314 (31·5)              17
  Chronic obstructive airway disease[b](#bjh14307-note-0005){ref-type="fn"}                            43 (8·5)            89 (9·0)                20
  Splenectomy (in past or during risk period)                                                          1 (0·2)             19 (1·9)                
  Organ transplant                                                                                     4 (0·8)             23 (2·3)                
  Liver cirrhosis                                                                                      13 (2·6)            24 (2·4)                2
  Haematological malignancy                                                                            60 (11·9)           210 (20·8)              13
  Carcinoma                                                                                            112 (22·3)          183 (18·2)              7
  Chemotherapy                                                                                         66 (13·1)           219 (21·8)              6
  Radiotherapy                                                                                         15 (3·0)            37 (3·6)                
  Leucopenia[c](#bjh14307-note-0006){ref-type="fn"}                                                    102 (20·2)          313 (31·0)              41
  Haematopoietic stem cell transplantation (autologous or allogeneic, in past or during risk period)   10 (2·0)            63 (6·2)                
  Graft versus host disease (acute or chronic)                                                         4 (1·5)             15 (0·8)                3
  Immunosuppressant medication[d](#bjh14307-note-0007){ref-type="fn"}                                  154 (30·9)          423 (42·4)              20
  GFR ≤ 30 ml/min[e](#bjh14307-note-0008){ref-type="fn"}                                               56 (11·1)           149 (14·8)              2
  Dialysis (either chronic or acute)[f](#bjh14307-note-0009){ref-type="fn"}                            31 (6·1)            98 (9·7)                

Values are *n* (%), unless otherwise stated. Numbers of patients for whom data on certain diagnoses and/or treatment modalities were not documented are presented as missing.

CABG, coronary artery bypass graft; GFR, glomerular filtration rate; ICU, intensive care unit; IQR, interquartile range.

Systemic or coronary atherosclerosis.

Chronic asthma bronchiale or chronic obstructive pulmonary disease.

At least one measured leucocyte count below lower limit of normal.

Medication under subcategory H02 (corticosteroids) or L04 (other immunosuppressants) within the Anatomical Therapeutic Chemical (ATC) classification index (WHO Collaborating Centre for Drug Statistics Methodology, [2016](#bjh14307-bib-0040){ref-type="ref"}).

GFR below 30 ml/min during at least 1 week of the risk period (with GFR calculated using the Modification of Diet in Renal Diseases \[MDRD\] equation; Levey *et al*, [1999](#bjh14307-bib-0024){ref-type="ref"}).

Haemodialysis, peritoneal dialysis, or continuous veno‐venous haemofiltration needed for at least 1 day during the risk period.
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Infections during the alloimmunisation risk period {#bjh14307-sec-0009}
--------------------------------------------------

Among all cases and controls, 473 patients were diagnosed with at least one infection during the alloimmunisation risk period. Of these, 417 suffered from bacterial infections, 53 from viral infections and 56 from fungal infections (Table [2](#bjh14307-tbl-0002){ref-type="table"}).

###### 

Infections diagnosed during the alloimmunisation risk period

  \(a\) Locus of bacterial infections according to severity                                                                        
  ----------------------------------------------------------- ----- -------------------------------------------------------------- -----
  Diagnosed in no. of patients                                116   Diagnosed in no. of patients                                   269
  Bacterial enteritis                                         12    Abdominal infections (including abscesses)                     87
  Catheter related[a](#bjh14307-note-0011){ref-type="fn"}     37    Arthritis, bursitis, myositis, fasciitis, infected haematoma   11
  Lower urinary tract infection                               36    Bacterial meningitis                                           5
  Skin and superficial wound infections                       25    Deep wound or skin infection                                   20
  Upper respiratory tract infection                           11    Endocarditis, mediastinitis, pericarditis                      21
                                                                    Infected foreign material                                      15
                                                                    Lower respiratory tract infection                              85
                                                                    Non‐abdominal abscesses                                        17
                                                                    Osteomyelitis, spondylodiscitis                                5
                                                                    Upper urinary tract infection                                  19

  \(b\) Microorganism genus (and species)                                                         
  ---------------------------------------------------------- ----- ------------------------------ ----
  Diagnosed in no. of patients                               117   Diagnosed in no. of patients   57
  Bacillus                                                   1     Bacteroides                    4
  Clostridium                                                1     Burkholdera                    1
  Corynebacterium                                            2     Capnocytophaga                 1
  Enterococcus                                               30    Enterobacter                   8
  Gemella                                                    2     Escheria (Coli)                23
  Listeria                                                   1     Neisseria (Meningitides)       1
  Micrococcus                                                1     Klebsiella                     11
  Staphylococcus                                             62    Proteus                        2
  Excluding coagulase negative                               22    Pseudomonas                    9
  Streptococcus                                              25    Serratia                       7
                                                                   Stenotrophomonas               1
  **Viral infections**                                             **Fungal infections**          
  Diagnosed in no. of patients                               53    Diagnosed in no. of patients   56
  Local viral infections                                           Aspergillus (pulmonary)        11
  BK (cystitis)                                              1     Candida                        42
  HSV (stomatitis)                                           13    Stomatitis                     10
  Respiratory virus[b](#bjh14307-note-0012){ref-type="fn"}   11    Candidaemia                    11
  Enteral virus[c](#bjh14307-note-0013){ref-type="fn"}       2     Other location                 22
  Disseminated viral diseases                                      Pneumocystis (jirovecii)       2
  Adenoviraemia                                              3     Penicillium (pulmonary)        1
  BK viraemia                                                1                                    
  Cytomegalovirus viraemia                                   11                                   
  Epstein Barr Virus viraemia                                2                                    
  Hepatitis C vireamia                                       6                                    
  Human Herpesvirus‐ 6 viraemia                              2                                    
  Human immunodeficiency virus                               3                                    
  Varicella Zoster Virus reactivation                        3                                    

Cumulative numbers per type of infection do not necessarily equal the number of patients diagnosed with this infection, as individual patients can have been infected with multiple microorganisms and types of infections.

Routine (tip) cultures from central catheters and catheter induced phlebitis.

Coronavirus (1), H1N1 virus (1), herpes simplex virus‐ 1 with bronchial location (1), influenza‐virus (2), para‐influenza virus (2), respiratory syncytial virus (1), rhinovirus (3).

Norovirus (1), rotavirus (1).
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For 222 of 269 patients (82·5%) diagnosed with a severe tissue‐invasive bacterial infection, the causal microorganism was identified by culture. For three of 53 virally‐infected patients, no PCR test was performed during the alloimmunisation risk period. These patients were nevertheless included based on their clinical condition: one patient receiving an allogeneic stem cell transplantation with an outbreak of varicella zoster, one patient receiving chemotherapy for Burkitt lymphoma with herpes labialis, and one patient with liver cirrhosis due to a chronic hepatitis C infection.

Identified confounders per alloimmunisation determinant are presented in Tables SII and SIII. As illustrated, control subjects with viral infections were younger, had received more red cell units, and were more often leucopenic as compared to those without viral infections. These differences were probably due to a higher frequency of haematological malignancies and associated treatment modalities.

Missing data for any identified confounder per determinant was at a maximum of 3·1%. CRP values were not measured in 343 patients (22·6%) during the risk period (Table SI).

The association between various types of infections and red cell alloimmunisation {#bjh14307-sec-0010}
---------------------------------------------------------------------------------

The number of cases and controls diagnosed per type of infection are presented in Table [3](#bjh14307-tbl-0003){ref-type="table"}. For some patients, the presence or absence of a certain type of infection could not be determined. The majority of these cases were due to an unestablished origin of the inflammatory condition (i.e. an infection or other inflammatory causes). In order to avoid misclassification, we omitted these patients from the corresponding analysis.

###### 

Association between (various types of) bacterial and viral infections and red cell alloimmunisation

  Type of infection            Cases, *N*/total   Controls, *N*/total   RR (95% CI)[a](#bjh14307-note-0016){ref-type="fn"}   Adjusted RR (95% CI)[b](#bjh14307-note-0017){ref-type="fn"}   Excluded from analysis
  ---------------------------- ------------------ --------------------- ---------------------------------------------------- ------------------------------------------------------------- ------------------------
  Bacterial infections                                                                                                                                                                     
  Tissue invasive infections   129/486            228/961               1·17 (0·90--1·51)                                    1·30 (0·98--1·74)                                             68
  Mild                         39/499             77/989                0·99 (0·66--1·49)                                    1·08 (0·70--1·66)                                             27
  Severe                       100/490            169/978               1·22 (0·92--1·62)                                    1·34 (0·97--1·85)                                             47
  Bacteraemia                  45/502             114/1003              0·75 (0·51--1·09)                                    0·89 (0·59--1·36)                                             10
  Gram‐positive                34/502             83/1003               0·78 (0·51--1·20)                                    1·08 (0·66--1·74)                                             10
  Gram‐positive, non‐CNS       24/504             61/1009               0·82 (0·40--1·67)                                    0·96 (0·56--1·65)                                             2
  Gram‐negative                13/505             44/1010               0·57 (0·30--1·09)                                    0·58 (0·13--1·14)                                             0
  Viral infections                                                                                                                                                                         
  All                          15/503             38/1003               0·72 (0·38--1·38)                                    1·56 (0·75--3·25)                                             9
  Local                        7/503              20/1003               0·71 (0·29--1·74)                                    1·80 (0·65--4·98)                                             9
  Disseminated                 10/505             20/1010               0·89 (0·40--2·02)                                    2·41 (0·89--6·53)                                             0
  Fungal infections                                                                                                                                                                        
  All                          12/501             44/1001               0·50 (0·25--0·99)                                    0·60 (0·29--1·25)                                             13
  Candidaemia                  4/505              7/1010                1·19 (0·31--4·55)                                    2·93 (0·54--15·89)                                            0
  Invasive aspergillus         1/503              10/1004               0·17 (0·02--1·42)                                    0·33 (0·03--3·28)                                             8

Patients for whom the presence or absence of a given infection could not be determined were excluded from the corresponding analysis.

RR, relative risk; 95% CI, 95% confidence interval; CNS, coagulase negative staphylococcus.

Adjusted for: number of transfused red cell units and hospital.

Additionally adjusted for identified potential confounders (for details, see Table SIII).
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Mild bacterial infections were not associated with alloimmunisation. Patients with a severe tissue‐invasive bacterial infection tended towards increased alloimmunisation risks \[adjusted RR 1·34 (95% CI 0·97--1·85); Table [3](#bjh14307-tbl-0003){ref-type="table"}\]. Relative risks increased to significance when these infections were accompanied with long‐lasting fever \[adjusted RR 3·06 (95% CI 1·57--5·96) with fever present for at least 7 days, Table [4](#bjh14307-tbl-0004){ref-type="table"}\]. The timing of fever i.e. occurring close to the implicated transfusion or at any time point during the risk period did not influence RRs (Table SIV). A sensitivity analysis on patients originally omitted from the analysis on severe bacterial infection (*N* = 47) did not change RRs (Table SV).

###### 

Infections and red cell alloimmunisation according to the presence of fever and its duration

  Type of infection             Fever       Cases, *N*/total   Controls, *N*/total   RR (95% CI)[a](#bjh14307-note-0020){ref-type="fn"}   Adjusted RR (95% CI)[b](#bjh14307-note-0021){ref-type="fn"}
  ----------------------------- ----------- ------------------ --------------------- ---------------------------------------------------- -------------------------------------------------------------
  Severe bacterial infection                                                                                                              
  −                                         390/490            809/978               ref.                                                 ref.
  \+                            --          17/490             48/978                0·72 (0·41--1·29)                                    0·79 (0·44--1·43)
  \+                            1--6 days   59/490             101/978               1·20 (0·84--1·71)                                    1·33 (0·91--1·99)
  \+                            ≥7 days     24/490             20/978                2·67 (1·40--5·07)                                    3·06 (1·57--5·96)
  Gram‐positive bacteraemia                                                                                                               
  −                                         468/502            921/1003              ref.                                                 ref.
  \+                            --          3/502              13/1003               0·51 (0·15--1·81)                                    0·88 (0·24--3·28)
  \+                            1--6 days   21/502             54/1003               0·72 (0·42--1·22)                                    0·92 (0·52--1·61)
  \+                            ≥7 days     10/502             15/1003               1·29 (0·55--3·03)                                    2·14 (0·84--5·41)
  Gram‐negative bacteraemia                                                                                                               
  −                                         492/505            966/1010              ref.                                                 ref.
  \+                            --          0/505              6/1010                0 (NC)                                               0 (NC)
  \+                            1--6 days   12/505             34/1010               0·70 (0·35--1·39)                                    0·71 (0·35--1·45)
  \+                            ≥7 days     1/505              4/1010                0·52 (0·04--6·30)                                    0·53 (0·04--6·62)
  Disseminated viral diseases                                                                                                             
  −                                         495/505            990/1010              ref.                                                 ref.
  \+                            --          4/505              7/1010                1·14 (0·33--3·97)                                    1·89 (0·50--7·15)
  \+                            1--6 days   4/505              9/1010                0·61 (0·16--2·38)                                    3·77 (0·64--22·24)
  \+                            ≥7 days     2/505              4/1010                1·12 (0·20--6·39)                                    2·58 (0·37--17. .82)

Only numbers of patients for whom the presence or absence of a given infection could be determined are presented.

RR, relative risk; 95% CI, 95% confidence interval; NC, not computable.

Adjusted for: number of transfused red cell units and hospital.

Additionally adjusted for identified potential confounders (for details, see Table SIII).

John Wiley & Sons, Ltd

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

Given that alloantibodies against E, C^w^, Le^a^, Le^b^, Lu^a^, and M can also form 'naturally', \[e.g. in response to microbial epitope exposure rather than to transfusion‐related red cell exposure (Reid *et al*, [2004](#bjh14307-bib-0029){ref-type="ref"})\] we evaluated a possible association between the induction of these antibodies and various infections using Pearson\'s chi‐square test. The distribution of alloantibodies known to also occur 'naturally' did not differ between patients with and without severe bacterial infections (Table [5](#bjh14307-tbl-0005){ref-type="table"}).

###### 

Specificity and frequency of first‐formed red cell alloantibodies according to the presence of various types of infections

  Alloantibody specificity                                              All patients, *N* (%)   No infection, *N* (%)   Severe bacterial infection, *N* (%)   Viral infection (local and disseminated), *N* (%)   Gram‐negative bacteraemia, *N* (%)
  --------------------------------------------------------------------- ----------------------- ----------------------- ------------------------------------- --------------------------------------------------- ------------------------------------
  anti‐C                                                                23 (4·0)                19 (5·2)                1 (0·9)                               0 (0)                                               1 (7·1)
  anti‐c                                                                41 (7·2)                25 (6·8)                8 (7·1)                               0 (0)                                               1 (7·1)
  anti‐E                                                                185 (32·3)              113 (30·7)              41 (36·4)                             4 (26·7)                                            5 (35·7)
  anti‐e                                                                5 (0·9)                 5 (1·4)                 0 (0)                                 0 (0)                                               0 (0)
  anti‐K                                                                126 (22·0)              88 (23·9)               21 (18·6)                             3 (20·0)                                            6 (42·9)
  anti‐C^w^                                                             19 (3·3)                10 (2·7)                4 (3·5)                               3 (20·0)                                            0 (0)
  anti‐Fy^a^                                                            31 (5·4)                24 (6·5)                4 (3·5)                               1 (6·7)                                             0 (0)
  anti‐Fy^b^                                                            5 (0·9)                 4 (1·1)                 1 (0·9)                               0 (0)                                               0 (0)
  anti‐Jk^a^                                                            54 (9·4)                37 (10·1)               8 (7·1)                               3 (20·0)                                            0 (0)
  anti‐Jk^b^                                                            7 (1·2)                 4 (1·1)                 2 (1·8)                               0 (0)                                               0 (0)
  anti‐Le^a^                                                            7 (1·2)                 2 (0·5)                 4 (3·5)                               0 (0)                                               0 (0)
  anti‐Le^b^                                                            3 (0·5)                 1 (0·3)                 1 (0·9)                               0 (0)                                               0 (0)
  anti‐Lu^a^                                                            32 (5·6)                19 (5·2)                9 (8·0)                               0 (0)                                               0 (0)
  anti‐Lu^b^                                                            0 (0)                   0 (0)                   0 (0)                                 0 (0)                                               0 (0)
  anti‐M                                                                22 (3·8)                14 (3·8)                5 (4·4)                               1 (6·7)                                             0 (0)
  anti‐N                                                                1 (0·2)                 0 (0)                   0 (0)                                 0 (0)                                               0 (0)
  anti‐S                                                                12 (2·1)                7 (1·9)                 4 (3·5)                               0 (0)                                               1 (7·1)
  anti‐s                                                                0 (0)                   0 (0)                   0 (0)                                 0 (0)                                               0 (0)
  (possibly) natural occurring[a](#bjh14307-note-0022){ref-type="fn"}   268 (46·7)              159 (43·2)              64 (56·6)                             8 (53·3)                                            5 (35·7)
  All antibodies                                                        573                     368                     113                                   15                                                  14
  Number of patients                                                    505                     325                     100                                   10                                                  13

Including: anti‐E, anti‐C^w^, anti‐Le^a^, anti‐Le^b^, anti‐Lu^a^, and anti‐M. No difference in distribution of (possibly) natural occurring alloantibodies was observed between patients with and without severe bacterial infections (*P* = 0·08), disseminated viral infections (*P* = 0·93), and Gram‐negative bacteraemia (*P* = 0·41).
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Interestingly, patients with a Gram‐negative bacteraemia tended to demonstrate reduced alloimmunisation rates \[adjusted RR 0·58 (95% CI 0·13--1·14)\], while Gram‐positive bacteraemia was not associated with red cell alloimmunisation (Table [3](#bjh14307-tbl-0003){ref-type="table"}). To exclude a potential dilution of an existing effect by contaminated blood cultures positive for CNS, we also evaluated the association of non‐CNS Gram‐positive bacteraemia with alloimmunisation. RRs from this analysis were identical to the originally calculated RRs.

Any viral disease tended to be associated with increased red cell alloimmunisation incidences. The adjusted RR associated with disseminated viral infections was 2·41 (95% CI 0·89--6·53). The presence of fever did not influence RRs of viral infections (Table [4](#bjh14307-tbl-0004){ref-type="table"}).

Fungal infections, as well as candidaemia and invasive aspergillus infections separately, were associated with heterogeneous RRs not reaching significance (Table [3](#bjh14307-tbl-0003){ref-type="table"}).

The association between laboratory indicators of inflammation and red cell alloimmunisation {#bjh14307-sec-0011}
-------------------------------------------------------------------------------------------

Neither leucocytosis nor CRP level was associated with red cell alloimmunisation. A sensitivity analysis on parameters determined within the week following the implicated transfusion did not change these results (Table SVI).

Discussion {#bjh14307-sec-0012}
==========

This study, the first of its kind, in transfused patients suggests a possible association between infectious conditions and red cell alloimmunisation. Specifically, our observations suggest alloimmunisation to be influenced by the type and intensity of, and the patient\'s inflammatory response to infections. In summary, severe (tissue‐invasive) bacterial and viral infections were associated with increased incidences of alloimmunisation \[RRs 1·34 (95% CI 0·97--1·85) and 2·41 (95% CI 0·89--6·53)\]. In contrast, Gram‐negative bacteraemia coincided with a twofold reduction of alloimmunisation risk \[RR 0·58 (95% CI 0·13--1·14)\].

Our findings certainly require additional confirmatory research. However, they seem to be biologically plausible and are in line with prior animal experiment observations (Hendrickson *et al*, [2006](#bjh14307-bib-0015){ref-type="ref"}, [2007](#bjh14307-bib-0016){ref-type="ref"}, [2008](#bjh14307-bib-0017){ref-type="ref"}; Smith *et al*, [2012](#bjh14307-bib-0034){ref-type="ref"}).

First, long‐lasting fever with severe bacterial infections was associated with a substantially increased risk \[RR 3·06 (95% CI 1·57--5·96)\]. Here, persistence of fever could have reflected the most severe bacterial infections inducing a profound inflammatory response. Alternatively, or additionally, fever might have been due to other concomitant inflammatory conditions. Yet, both explanations are consistent with the 'danger model' (Matzinger, [1994](#bjh14307-bib-0026){ref-type="ref"}) which postulates that an immune response is facilitated by pathogen‐associated molecular patterns or structures released from cells undergoing stress (Matzinger, [1994](#bjh14307-bib-0026){ref-type="ref"}; Gallucci & Matzinger, [2001](#bjh14307-bib-0011){ref-type="ref"}; Kawai & Akira, [2010](#bjh14307-bib-0020){ref-type="ref"}).

Second, although the 95% CI encompassing 1 (i.e. a null effect) warrants firm conclusions, we observed substantially increased alloimmunisation rates in patients with systemic viral infections. Murine experiments showed similar effects for poly(I:C) (Hendrickson *et al*, [2006](#bjh14307-bib-0015){ref-type="ref"}, [2007](#bjh14307-bib-0016){ref-type="ref"}, [2008](#bjh14307-bib-0017){ref-type="ref"}; Smith *et al*, [2012](#bjh14307-bib-0034){ref-type="ref"}), a synthetic viral RNA analogue that agonizes Toll‐like receptor (TLR) 3 (Alexopoulou *et al*, [2001](#bjh14307-bib-0002){ref-type="ref"}). These poly(I:C) effects were attributed to an increased dendritic cell consumption of transfused cells with upregulation of costimulatory molecules, and activation and proliferation of naive CD4^+^ antigen‐specific T‐cells (Hendrickson *et al*, [2007](#bjh14307-bib-0016){ref-type="ref"}, [2008](#bjh14307-bib-0017){ref-type="ref"}). An existing molecular mimicry between certain viral peptides and CD4^+^ T‐cell red cell antigen epitopes was also suggested, although observed effects in polyomavirus infected mice did not reach statistical significance (Hudson *et al*, [2010](#bjh14307-bib-0019){ref-type="ref"}).

Although we did not analyse the association between latent viral infections and red cell alloimmunisation, these might also be relevant. In addition, the assessment of possible different effects of RNA and DNA viruses was prevented by low event numbers.

Third, we observed a twofold alloimmunisation incidence reduction during Gram‐negative bacteraemia. Analogous to viral infections, these findings require confirmatory research. Yet, they again corroborate animal experiments showing significantly attenuated alloimmunisation responses upon lipopolysaccharide (LPS) pretreatment in mice (Hendrickson *et al*, [2008](#bjh14307-bib-0017){ref-type="ref"}). LPS, an endotoxin in the outer cell membrane of Gram‐negative bacteria, strongly stimulates innate immunity by agonizing TLR4 on macrophages and dendritic cells. Conversely, LPS is also implicated in a transient, possibly self‐protective immune paralysis, known as LPS tolerance (Lauw *et al*, [2000](#bjh14307-bib-0023){ref-type="ref"}; Weijer *et al*, [2002](#bjh14307-bib-0039){ref-type="ref"}; Gould *et al*, [2004](#bjh14307-bib-0012){ref-type="ref"}). Restimulation with LPS in this respect initiates blockage of CD4^+^ T cell functioning via impaired release of tumour necrosis factor α, interleukin (IL)12 and IL18 from monocytes and dendritic cells, together with a diminished upregulation of major histocompatibility complex class‐II and costimulatory molecules (Mattern *et al*, [1998](#bjh14307-bib-0025){ref-type="ref"}; Gould *et al*, [2004](#bjh14307-bib-0012){ref-type="ref"}). While regulatory T cells selectively express TLRs (including TLR4), their LPS‐induced proliferation might also contribute to the observed effects in both mice and humans (Caramalho *et al*, [2003](#bjh14307-bib-0005){ref-type="ref"}). Finally, we cannot exclude an indirect role for Gram‐negative bacteraemia on red cell alloimmunisation due to their common association with other modulators. Indeed, suppressed mitogenic B and T lymphocyte responses were observed following administration of antibiotics, including cephalosporins, an antibiotic class frequently used in the treatment of Gram‐negative bacterial infections (Borowski *et al*, [1985](#bjh14307-bib-0003){ref-type="ref"}; Pomorska‐Mol *et al*, [2015](#bjh14307-bib-0028){ref-type="ref"}).

In an intriguing contrast to the effects observed for Gram‐negative bacteraemia, we did not observe any association between Gram‐positive bacteraemia and red cell alloimmunisation. A common lower degree of acute inflammation evoked by gram‐positive as compared to gram‐negative bloodstream infections due to differing virulence mechanisms forms one hypothetical explanation (Wang *et al*, [2003](#bjh14307-bib-0038){ref-type="ref"}; Gould *et al*, [2004](#bjh14307-bib-0012){ref-type="ref"}; Abe *et al*, [2010](#bjh14307-bib-0001){ref-type="ref"}).

Despite the RRs for fungal infections not differing significantly from those for Gram‐negative bacteraemia, the heterogeneous RRs for individual fungal microorganisms and the lack of other supportive evidence prevent tentative inferences. Indeed, in contrast to our estimated RR, one report suggested neonatal alloimmunisation to be related to a disseminated histoplasmosis infection (Hata *et al*, [2013](#bjh14307-bib-0014){ref-type="ref"}).

The ultimate goal of our study would be to establish an accurate alloimmunisation prediction model, serving as a practical tool for risk‐based extended matching. Such a model would be most feasible when based on routinely measured patient parameters. In this perspective, we did not observe any association of the level of leucocytosis and CRP with alloimmunisation, possibly due to the multifactorial nature of these parameters. Other biomarkers, e.g. cytokine levels and immune cell subsets, might be better discriminative; however, they could not be evaluated in the current study.

Our study design, results and interpretations require additional remarks:

First, our incidence‐density sampling strategy guarantees that selected controls were similarly exposed as their matched cases (Rothman, [2007](#bjh14307-bib-0030){ref-type="ref"}). Hereby, our RRs are not influenced by transfusion burden, being a main determinant of red cell alloimmunisation (Zalpuri *et al*, [2012b](#bjh14307-bib-0044){ref-type="ref"}; Evers *et al*, [2016](#bjh14307-bib-0009){ref-type="ref"}).

Second, by identifying the implicated transfusion, we could study conditions present at that given time. As the duration of alloimmunisation modulation is currently unknown and will also probably differ per risk factor, we chose a seemingly large risk period to precede the implicated transfusion. Although one could argue that this strategy could possibly dilute some effects, on the other hand, it assures inclusion of most factors of influence at the time of exposure. For example, repeated LPS exposure might induce a state of tolerance persisting for up to 30 days (Cross, [2002](#bjh14307-bib-0007){ref-type="ref"}). In addition, a recent study showed that poly(I:C) facilitates red cell alloimmunisation for at least 14 days with its maximum effect reached 7 days after administration (Elayeb *et al*, [2016](#bjh14307-bib-0008){ref-type="ref"}). As a validation of our chosen risk period length, a sensitivity analysis on infections diagnosed during the week preceding or following the implicated transfusion did not change our conclusions (data not shown). Similarly, only the duration of fever accompanying severe bacterial infections, rather than its timing in the risk period, affected alloimmunisation. As we aimed to target the most likely first initiation of an alloimmune response, we limited the risk period to the first 7 days following the implicated transfusion.

Third, actual lag periods per antigen‐specific antibody are currently unknown. As such, our chosen lag period of 7 days might not completely have prevented the exclusion of patients demonstrating recall responses, including women immunised due to prior pregnancies. Direct antiglobulin tests were not performed on a routine basis shortly following transfusion and as such were of no help in identifying these patients. However, as non‐RhD alloantibodies form in only 0·33% of first trimester pregnancies (Koelewijn *et al*, [2008](#bjh14307-bib-0021){ref-type="ref"}), we believe that a substantial influence of previous pregnancies is unlikely. Moreover, erroneously considering a substantial amount of boosting reactions as primary alloimmunisation events would have biased our RRs towards the null‐effect. Indeed, a sensitivity analysis in which we excluded the 53 patients in whom alloantibodies were discovered during the second week following their first antigen‐incompatible transfusion did not substantially change RRs (data not shown). In conclusion, we believe the eventual bias due to our choice of the lag period to be small.

Fourth, to avoid invalid inferences due to misclassification, we did not define patients with a non‐established aetiology of their inflammatory phenotype as exposed patients. For example, for a vascular compromised patient diagnosed with osteomyelitis, wound cultures positive for *Staphylococcus Aureus* might have represented normal skin flora colonization of a primary ischaemic wound. Consequently, the analysis on severe bacterial infections did not include this patient. A sensitivity analysis confirmed our results not to be affected by this possible misclassification bias.

In conclusion, our data suggest a potential risk modifying influence of infection‐associated inflammation on red cell alloimmunisation in transfused patients. Alloimmunisation seems to be induced by severe bacterial or viral infections, but might be skewed towards protection in the presence of Gram‐negative bacteraemia. Further confirmatory research is needed to ultimately identify the high‐risk patient and, consequently, better target the allocation of more extensively matched red cell units.

Authorship {#bjh14307-sec-0014}
==========

JJZ and JGB designed the study. DE, JT, and SZ collected the data. DE, JJZ, RAM, MH and JGB analysed and interpreted the data. DE, JJZ, MH, and JGB wrote the manuscript. All other authors revised and approved the final manuscript.

Disclosure of conflicts of interest {#bjh14307-sec-0015}
===================================

The authors declare that they have no conflict of interest relevant to the work presented in this manuscript.

Supporting information
======================

###### 

**Data S1.** Study period per participating hospital and the used multiple imputation model.
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